IFNG and rheumatoid arthritis: We elected to use tofacitinib as a pan JAK inhibitor, as it has previously been shown to be effective against IFN-γ (46) and IL-13 (35) signaling in vitro, and safety and efficacy have been demonstrated in numerous clinical trials (44) including the treatment of rheumatoid arthritis.